Suzhou Ribo Life Science Co., Ltd.

Ribo Submits European Clinical Trial Application for a Novel Dual Targeting siRNA SR122 for Mixed and Severe Dyslipidemia, Further Strengthening Its Footprint in the Area of Lipid Disorder

Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the submission of a…